跳至主要内容
临床试验/ACTRN12622000218796
ACTRN12622000218796尚未招募未知

A Main Study to Determine the Diagnostic Utility of the ultrasmall superparamagnetic iron oxide (USPIO) MRI Scan in Tracking Macrophages in Patients with Glioblastoma and brain tumour metastases

Tania Slatter0 个研究点目标入组 80 人开始时间: 2022年2月7日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Non-randomised trial
主要目的
Diagnosis
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • 1.Patients with an imaging diagnosis based on the baseline diagnostic MRI scan (gadolinium contrast) of primary stage 3 or 4 astrocytoma, or brain tumour metastasis.
  • 2.No steroid treatment that has been administered to the patients between the time of the baseline diagnostic scan and the ferumoxytol infusion.

排除标准

  • 1.Patients who are younger than 18 years old.
  • 2.Patients who are pregnant or breast feeding.
  • 3.Patients who have known allergy to iron preparations or other medication allergies.
  • 4.Patients who have haemochromatosis or known clinically significant liver function abnormalities.
  • 5.The initial diagnostic MRI demonstrates intracranial haemorrhage, calcification or other susceptibility blooming artifacts.

研究者

发起方
Tania Slatter

相似试验

An interventional trial comparing ferumoxytol and... | 临床试验